Literature DB >> 20375844

Influence of ultrasound induced cavitation on magnetic resonance imaging contrast in the rat liver in the presence of macromolecular contrast agent.

Nora Frulio1, Hervé Trillaud, Roel Deckers, Sébastien Lepreux, Chrit Moonen, Bruno Quesson.   

Abstract

OBJECTIVES: Local drug delivery by ultrasound (US)-induced cavitation is a promising strategy for increasing the drug concentration at the target location and for decreasing the systemic toxicity effects. The presence of microbubbles during sonication at the targeted location improves the likelihood for cavitation that can be exploited to increase the capillary permeability. The objective of this work was to evaluate the magnetic resonance imaging (MRI) contrast changes in hepatic tissue in vivo, induced by US-triggered cavitation and destruction of microbubbles (Sonovue), in the presence of a coinjected blood pool MRI contrast agent (Vistarem) used as a reporter macromolecule. The potential tissue damage induced by microbubbles destruction was also evaluated by histology.
METHOD: The change in the hepatic distribution of the macromolecular MRI contrast agent associated with cavitation was monitored at 1.5 T with a look-locker fast inversion recovery sequence to map the longitudinal relaxation rates, before and during 1 hour after intravenous administration of Vistarem and Sonovue. In 1 group of rats (n = 5), these microbubbles were immediately destroyed with a clinical echograph, using a high mechanical index (MI = 1.5) at low frequency (2 MHz). The control group (n = 7) received identical injections without application of US. The parametric relaxation rate images were computed, and the changes in time were analyzed to account for the potential effect of microbubble destruction by US on the permeability of the hepatic vessels. The animals were killed 1 day after the experiment for routine histology of the liver.
RESULTS: For both groups of animals, after an initial increase, a transient decay of the longitudinal relaxation rate was observed, followed by a constant plateau after 20 minutes. The analysis of the mean relaxation rates in the liver showed significant (P < 0.01) higher values for the group with destruction of microbubbles as compared with the control group. The US-triggered cavitation and destruction of microbubble with the proposed protocol suggests an increased concentration of Vistarem of a factor 2 in the hepatic tissue. No tissue damage was observed at the microscopic analysis.
CONCLUSION: The absence of tissue alterations indicates that the destruction of this US contrast agent could be safe in vivo under an appropriate choice of the sonication parameters. This approach opens new perspectives for translation toward clinical applications of local drug delivery. Ultrasound-mediated microbubble destruction may help in increasing the local concentration of a drug currently limited by the endothelial barrier. In addition, it may help in reducing the systemic toxicity to normal cells in standard chemotherapies, because the enhanced capillary permeability effect can be spatially adjusted by selecting the sonicated region.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20375844     DOI: 10.1097/RLI.0b013e3181dac2a7

Source DB:  PubMed          Journal:  Invest Radiol        ISSN: 0020-9996            Impact factor:   6.016


  10 in total

Review 1.  Phase-shift, stimuli-responsive perfluorocarbon nanodroplets for drug delivery to cancer.

Authors:  Natalya Rapoport
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2012-06-22

Review 2.  Phase-shift, stimuli-responsive drug carriers for targeted delivery.

Authors:  Brian E O'Neill; Natalya Rapoport
Journal:  Ther Deliv       Date:  2011-09

Review 3.  Novel delivery approaches for cancer therapeutics.

Authors:  Ashim K Mitra; Vibhuti Agrahari; Abhirup Mandal; Kishore Cholkar; Chandramouli Natarajan; Sujay Shah; Mary Joseph; Hoang M Trinh; Ravi Vaishya; Xiaoyan Yang; Yi Hao; Varun Khurana; Dhananjay Pal
Journal:  J Control Release       Date:  2015-10-09       Impact factor: 9.776

4.  Focused ultrasound-mediated drug delivery to pancreatic cancer in a mouse model.

Authors:  Natalya Rapoport; Allison Payne; Christopher Dillon; Jill Shea; Courtney Scaife; Roohi Gupta
Journal:  J Ther Ultrasound       Date:  2013-07-01

5.  Inhibition of prostate cancer growth using doxorubicin assisted by ultrasound-targeted nanobubble destruction.

Authors:  Xiaozhou Fan; Luofu Wang; Yanli Guo; Xingyu Xiong; Lianhua Zhu; Kejing Fang
Journal:  Int J Nanomedicine       Date:  2016-07-29

6.  Recent advances of sonodynamic therapy in cancer treatment.

Authors:  Guo-Yun Wan; Yang Liu; Bo-Wei Chen; Yuan-Yuan Liu; Yin-Song Wang; Ning Zhang
Journal:  Cancer Biol Med       Date:  2016-09       Impact factor: 4.248

7.  Sonodynamic therapy in combination with photodynamic therapy shows enhanced long-term cure of brain tumor.

Authors:  Ballav M Borah; Joseph Cacaccio; Farukh A Durrani; Wiam Bshara; Steven G Turowski; Joseph A Spernyak; Ravindra K Pandey
Journal:  Sci Rep       Date:  2020-12-11       Impact factor: 4.379

Review 8.  The crosstalk between sonodynamic therapy and autophagy in cancer.

Authors:  Yujie Zhang; Yuanru Zhao; Yuanyuan Zhang; Qingguang Liu; Mingzhen Zhang; Kangsheng Tu
Journal:  Front Pharmacol       Date:  2022-08-15       Impact factor: 5.988

9.  Design and evaluation of a hybrid radiofrequency applicator for magnetic resonance imaging and RF induced hyperthermia: electromagnetic field simulations up to 14.0 Tesla and proof-of-concept at 7.0 Tesla.

Authors:  Lukas Winter; Celal Özerdem; Werner Hoffmann; Davide Santoro; Alexander Müller; Helmar Waiczies; Reiner Seemann; Andreas Graessl; Peter Wust; Thoralf Niendorf
Journal:  PLoS One       Date:  2013-04-22       Impact factor: 3.240

10.  Low-frequency ultrasound enhances chemotherapy sensitivity and induces autophagy in PTX-resistant PC-3 cells via the endoplasmic reticulum stress-mediated PI3K/Akt/mTOR signaling pathway.

Authors:  Yuqi Wu; Xiaobing Liu; Zizhen Qin; Li Hu; Xiangwei Wang
Journal:  Onco Targets Ther       Date:  2018-09-10       Impact factor: 4.147

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.